Clinical Trials

  • Study of Selinexor in Pediatric Solid Tumors, including CNS Tumors

    Principal Investigator:

    Alice Lee, MD
    We are testing new experimental drugs such as selinexor in the hopes of finding a treatment that may be effective against tumors that have come back or that have not responded to standard therapy. The goals of this study are: To find the highest safe dose of selinexor that can be given without causing severe side effects; To learn what kind of side effects selinexor can cause; To learn more about the pharmacology (how your body handles the drug) of selinexor; To learn more about the biology of selinexor in blood and tumor tissue; To determine whether selinexor is a beneficial treatment for...

  • Testing combination drugs in children with solid tumors that have come back or are resistant to current anti-cancer therapy

    Principal Investigator:

    Alice Lee, MD
    This is a Phase 1 multicenter study of pevonedistat in combination with Temozolomide and Irinotecan in pediatric patients with refractory solid tumors, including CNS tumors and lymphoma. The study treatment is considered experimental because pevonedistat is not approved by the United States (US) Food and Drug Administration (FDA) for treating pediatric patients with refractory solid tumors, including CNS tumors and lymphoma. The purpose of this study is to estimate the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of pevonedistat administered in combination with...

Pages